Arcus Biosciences Retains Rights to Casdatifan, a Potential Best-in-Class HIF-2a Inhibitor, and Announces Pricing of $150 Million Common Stock Offering

$RCUS
Biotechnology: Pharmaceutical Preparations
Health Care
Get the next $RCUS alert in real time by email

Weekly insight reads limit reached.

Join Quantisnow to enjoy unlimited reads, alerts, live feeds, and more.

Meet Quantisnow

Stock alerts. Live news feeds. Press releases. Insider trading. FDA approvals & more.

Invest smarter

A better trading workflow

Access market-moving news before they break out to the general public. Let Quantisnow cut out the noise and only receive insights that matter.

Live feeds
Real-time news feeds for Press Releases, SEC Filings, FDA approvals, market insights and more.
Custom filters
Filter out the noise with company filters, market cap filters, price filters and more.
Audio Squawk
Multitask with confidence and let Quantsinow read breaking news out loud.
Product screenshot
Quantisnow AI Features

Save time

Unlock Insights with AI

Get quick summaries and precise Q&A for every insight, empowering you to make informed decisions without sifting through entire press releases and lengthy SEC filings.

Get alerted immediately

All your stock market alerts in one place

Quantisnow alerts are fast, customizable, and versatile.

Email alerts
Subscribe to your favorite stocks and receive email alerts each time a news pops up.
App notifications
Reduce alerting latency with in-app notifications. Same as email alerts, but faster.
Webhooks
Integrate with Quantisnow programmatically and receive live insights via webhooks
Granular alerts
Want to receive Press Releases but no SEC filings? No problem - Quantisnow alerts are highly customizable and can seemlessly tailor to your trading needs.

Elevate your trading.
Start using Quantisnow today.

Never miss an update.

App screenshot

Simple no-tricks pricing

One membership with full access and no delays.

Quantisnow Plus

Your personal trading assistant for just $39/month.

What's included

  • Live feeds
  • Audio squawk
  • Compact mode in feeds
  • Email alerts
  • App push alerts
  • Unlimited insights reads
  • Unlimited subscriptions
  • Advanced filters in live feeds
  • Support
  • No ads
  • AI-generated summaries and Q&A

One membership - all access

$39/month

Get access

$39/month with yearly billing, $49/month with monthly billing

News insights ingested and delivered in real time
5 million+
Real-time news alerts sent out to Quantisnow users
700,000+
Latency of news delivery pipelines to users via mobile app, webhooks, and email
<100ms
Get the next $RCUS alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$RCUS

DatePrice TargetRatingAnalyst
2/26/2025$18.00 → $24.00Neutral → Buy
H.C. Wainwright
10/21/2024$20.00Neutral
H.C. Wainwright
10/8/2024$29.00Overweight
Wells Fargo
11/18/2022$33.00Neutral
BofA Securities
10/11/2022$40.00Overweight
Morgan Stanley
11/19/2021$42.00 → $53.00Buy
Citigroup
11/19/2021$48.00 → $60.00Overweight
Barclays
11/18/2021$68.00 → $100.00Outperform
SVB Leerink
More analyst ratings

$RCUS
Press Releases

Fastest customizable press release news feed in the world

See more
  • Arcus Biosciences Announces New Employment Inducement Grants

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that the Compensation Committee of the Company's Board of Directors granted twelve new employees options to purchase a total of 42,920 shares of the Company's common stock at an exercise price per share of $9.12, which was the closing price on March 24, 2025, and restricted stock units to acquire a total of 21,650 shares of the Company's common stock. The equity awards were granted pursuant to the Company's 2020 Inducement Plan, which was approved by the Company's Board of Directors in Janua

    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arcus Biosciences to Participate in Two Upcoming Investor Conferences

    Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, announced that its management team will participate in the following upcoming investor conferences in March: Leerink Global Healthcare Conference 2025 Date: Wednesday, March 12th, 2025 Location: Miami Beach, FL Format: Fireside chat & 1x1 meetings Time: 8:00 a.m. ET Barclays 27th Annual Global Healthcare Conference Date: Thursday, March 13th, 2025 Location: Miami Beach, FL Format: Fireside chat & 1x1 meetings Time: 8:00 a.m. ET Live webcasts of the fireside chats and panel will be available by visiting the

    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arcus Biosciences Reports Fourth-Quarter and Full-Year 2024 Financial Results and Provides a Pipeline Update

    New data from the Phase 1/1b ARC-20 study showed that casdatifan improved upon the rate of primary progression, overall response rate (ORR) and progression-free survival (PFS) relative to published data from studies with HIF-2a inhibitors to date Initiation of the Phase 3 study for PEAK-1 evaluating casdatifan in combination with cabozantinib versus cabozantinib in immuno-oncology (IO)-experienced patients with clear cell renal cell carcinoma (ccRCC) is expected in the first half of 2025; initial data from the cohort of ARC-20 evaluating casdatifan plus cabozantinib are expected to be presented in mid-2025 Arcus completed a $150 million financing and continues to be well positioned

    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RCUS
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$RCUS
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$RCUS
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$RCUS
SEC Filings

See more

$RCUS
Leadership Updates

Live Leadership Updates

See more
  • Arcus Biosciences Announces New Employment Inducement Grants

    Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Richard Markus, M.D., Ph.D., the Compensation Committee of the Company's Board of Directors granted Dr. Markus an option to purchase 305,328 shares of the Company's common stock at an exercise price per share of $12.45, which was the closing price on February 10, 2025, and restricted stock units to acquire a total of 75,193 shares of the Company's common stock. In addition to the awards to Dr. Markus, the Co

    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arcus Biosciences Appoints Richard Markus, M.D., Ph.D. as Chief Medical Officer

    Dr. Markus will oversee Arcus's clinical development organization and portfolio that includes seven clinical-stage programs with multiple ongoing Phase 3 studies   Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced that Richard Markus, M.D., Ph.D., has been appointed chief medical officer (CMO) effective January 31, 2025. Dr. Markus replaces Dimitry Nuyten, M.D., Ph.D., who will be leaving the company at the end of January to pursue other opportunities. Dr. Markus's responsibilities will include oversight of Arcus's clinical development

    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arcus Biosciences Announces New Employment Inducement Grants

    Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, in connection with the appointment of the Company's new Chief Medical Officer, Dimitry S.A. Nuyten, M.D., Ph.D, the Compensation Committee of the Company's Board of Directors granted Dr. Nuyten an option to purchase 170,000 shares of the Company's common stock at an exercise price per share of $26.00, which was the closing price on August 23, 2022, and restricted stock units to acquire a total of 42,500 shares of the Company's common stock. In addition to the awards to Dr. Nuyten, the Compensation Committee granted fifteen other new emplo

    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RCUS
Financials

Live finance-specific insights

See more
  • New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer

    A 9.7-month median progression-free survival (mPFS) was reached for the 50mg twice-daily (BID) casdatifan monotherapy cohort of the Phase 1/1b ARC-20 study; mPFS was not yet reached for other cohorts Across all three monotherapy cohorts presented, casdatifan demonstrated improvements in the rate of primary progression, overall response rate (ORR) and progression-free survival (PFS) relative to published data from studies with HIF-2a inhibitors to date Arcus will host a conference call to discuss these data at 5:00 AM PT / 8:00 AM ET on Tuesday, February 18, 2025 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiate

    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arcus Biosciences to Present New Data from Casdatifan, a HIF-2a Inhibitor, in an Oral Presentation at the 2025 ASCO GU Symposium

    New data from ARC-20, a Phase 1/1b study of the HIF-2a inhibitor casdatifan in clear cell renal cell carcinoma (ccRCC), will be presented in a rapid oral session by Dr. Toni Choueiri, Dana-Farber Cancer Institute The presentation will include initial data from the 100mg once-daily (QD) tablet cohort and updated data for the 50mg twice-daily (BID) and 50mg QD cohorts Arcus will host a conference call to discuss the ARC-20 data at 5:00 AM PT / 8:00 AM ET on Tuesday, February 18, 2025 Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announc

    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care
  • Arcus Biosciences Reports Third-Quarter 2024 Financial Results and Provides a Pipeline Update

    Data from the Phase 1/1b ARC-20 study of casdatifan were presented at an oral plenary session at the 2024 EORTC-NCI-AACR Symposium; a low rate of primary progression (19%) and promising objective response rate (34% with 2 responses pending confirmation, 25% confirmed) for the 100mg daily (50mg twice-daily) cohort of heavily pretreated patients with clear-cell renal cell carcinoma (ccRCC) support a potential best-in-class profile Arcus announced a clinical trial collaboration agreement with AstraZeneca to evaluate casdatifan in combination with volrustomig, an investigational PD-1/CTLA-4 bispecific antibody, in patients with immuno-oncology (IO)-naive ccRCC Data from the randomized ARC-

    $RCUS
    Biotechnology: Pharmaceutical Preparations
    Health Care

$RCUS
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more